Targeted Drug Delivery Technologies: Players, products & prospects to 2018 (Volume IV)

This major strategic analysis provides a detailed insight into the current and future market for targeted drug delivery technology.

Additional Information

Targeted Delivery

By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.

Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.

The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.

Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products. There are significant opportunities for future commercial developments within the pharmaceutical industry. These include:

Cost-effective production of antibodies and antibody fragments for drug targeting;
Development of new polymers and biopolymers that may be utilised in the safe and efficient targeted delivery of drugs and pro-drugs into host cells;
Development and selective targeting of macromolecules to improve intracellular uptake and tissue specificity;
Development of inactive pro-drugs for tissue specific release;
Extended product life-cycles through the development of targeted formulations;
Identification of new targeting ligands to improve the targeted delivery of small molecules and macromolecules;
Utilisation of multiple targeting ligands to address the needs of patient sub-types;
Combined technology platforms to develop targeted therapeutics and diagnostics in a single molecule.

A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.

This report is part of a major new 4-volume strategic analysis

Drug Delivery Technologies:
Players, Products & Prospects to 2018

Focusing on the sectors that are driving growth

VOLUME I
CONTROLLED- RELEASE

VOLUME II
NANOTECHNOLOGY

VOLUME III
NUCLEIC ACID DELIVERY

VOLUME IV
TARGETED DELIVERY

EXECUTIVE SUMMARY & INTRODUCTION
- Overview of delivery technologies for targeted delivery: past, present & future
- Systemic targeted delivery: motivators & resistors
TARGETED DELIVERY TECHNOLOGIES
- Types of systemic targeted delivery platform in development in the pharma industry
- Targeting ligands
- Antibody fragment conjugate delivery
- Antibody-directed enzyme pro-drug targeted delivery
- Peptide-induced release for targeted delivery
- Small molecule conjugate delivery
- Nucleomic mediated targeted intranuclear delivery
- Cobalamin mediated targeted intracellular delivery
- Non-biological targeting platforms
- Magnetically and Photosensitive targeted delivery
- Current therapeutic applications for targeted delivery
- Leading systemic targeted products in development
- Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading targeted drug delivery companies
- Strategic partnerships & acquisitions
- Intellectual property
THE TARGETED DELIVERY MARKET
- Now 2009: Approved targeted delivery product sales
- Future 2018: Global targeted-release product sales and novel targeted delivery product sales
COMPETITOR ANALYSIS
Detailed analysis of leading companies covering:
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products utilising the delivery technology
- Competitor ratio analysis
Companies analysed
- Access Pharmaceuticals, Inc.
- ALZA Corporation (Johnson & Johnson)
- ArmaGen Technologies, Inc.
- Avidimer Therapeutics, Inc.
- Calando Pharmaceuticals, Inc.
- Cell Therapeutics, Inc.
- Cerulean Pharma, Inc.
- Copernicus Therapeutics, Inc.
- CytImmune Sciences, Inc.
- Diatos S.A.
- Enzon Pharmaceuticals, Inc.
- Endocyte Inc.
- Eurand N.V.
- ImmunoGen, Inc.
- ImaRx Therapeutics, Inc.
- NanoBioMagnetics, Inc.
- Nanobiotix
- NanoCarrier, Inc.
- Nano Interface Technology
- Nektar Therapeutics
- NeoPharm
- Novosom AG
- PCI Biotech Holding ASA
- Quest PharmaTech, Inc.
- Seattle Genetics
- Spherics Pharmaceuticals, Inc
- Starpharma Holdings, Ltd
- Supratek Pharma Inc.
- Tekmira Pharmaceuticals Corporation
APPENDICIES
- Global targeted approved drug sales 2008-2018
- Global targeted development drug sales 2008-2018
- Key targeted delivery companies by 2018

Unique company & technology evaluation
It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.

In this report we present a précis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:

Proprietary delivery technology
Applications of the delivery technology within the pharmaceutical industry
Management/technical expertise of the delivery specialist
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology

We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on their relative attributes.

Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:

The technology
Comparison of delivery platforms within each area including: activated, degradation or diffusion for controlled-release systems; nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platforms for targeted delivery systems
The application of the technology within a number of therapy areas
Route of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additional features such as bioerodible materials etc
The current status of the technology in clinical development or following approval
Number of approved and marketed products, clinical or preclinical development candidates, single or multiple products.
Competition within the technology arena
Alternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors.
The drug delivery specialist’s expertise
Number of drug delivery systems in development, strategic alliances, financial position, marketing presence.
The product portfolio
Drug delivery systems under evaluation, products in development, commercialisation/development partnerships.
Potential drug sales
Based on key events such as market, competition, patent expiry, time of entry into the market.

About the Author
Dr Cheryl Barton is a highly regarded independent consultant with over 16 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer’s disease to schizophrenia. Dr Barton subsequently joined Dutch investment bank ABN Amro NV as a senior equity analyst where she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthélabo, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton founded a consulting business (www.Pharmavision.co.uk) to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.